scholarly journals Predictors of Bleeding in Patients with Symptomatic Peripheral Artery Disease: A Cohort Study Using the Health Improvement Network (THIN) in the UK

2019 ◽  
Vol 58 (6) ◽  
pp. e43
Author(s):  
Luis A. García Rodríguez ◽  
F. Gerry R Fowkes ◽  
Saga Johansson ◽  
Alaster M. Allum ◽  
Lucía Cea Soriano
2018 ◽  
Vol 118 (06) ◽  
pp. 1101-1112 ◽  
Author(s):  
Lucía Cea Soriano ◽  
F. Gerry Fowkes ◽  
Alaster Allum ◽  
Saga Johansson ◽  
Luis García Rodriguez

AbstractThe purpose of this analysis was to assess potential predictors of intra-cranial bleeding (ICB) and gastrointestinal bleeding (GIB) in patients with symptomatic peripheral artery disease (PAD) in UK primary care. Patients with symptomatic PAD diagnosed from 2000 to 2010 were identified from The Health Improvement Network (THIN; N = 28,484). A nested case–control analysis, adjusted for potential confounders, was performed to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for potential predictors of ICB or GIB. For GIB, follow-up was restricted to Hospital Episode Statistics-linked THIN practices. Median follow-up was 6 years. For ICB (153 cases), the OR (95% CI) was 3.85 (1.33–11.13) for previous ICB, 0.90 (0.61–1.34) for treated hypertension, 1.59 (0.65–3.87) for untreated hypertension and 1.38 (0.80–2.36) for current smoking. ORs for ICB were 0.78 (0.50–1.21), 0.40 (0.09–1.82) and 1.27 (0.47–3.47) with use of acetylsalicylic acid (ASA), clopidogrel and warfarin monotherapy, respectively, compared with non-use of such therapy. For GIB (506 cases), the OR was 1.40 (1.05–1.86) for peptic ulcer disease, 3.20 (1.81–5.64) for dual anti-platelet therapy use, 1.96 (1.46–2.64) for non-steroidal anti-inflammatory drug (NSAID) use and 1.01 (0.80–1.28) for proton pump inhibitor use. ORs for GIB were 1.78 (1.39–2.30), 2.03 (1.05–3.93) and 1.25 (0.72–2.16) with ASA, clopidogrel and warfarin monotherapy, respectively, compared with non-use. Previous ICB was a risk factor for ICB. Use of anti-platelet therapy or NSAIDs increased GIB risk. Identifying bleeding predictors could help optimize treatment strategies for patients with PAD.


Author(s):  
Diana Thomas Manapurathe ◽  
Joseph Vaughan Moxon ◽  
Smriti Murali Krishna ◽  
Sophie Rowbotham ◽  
Frank Quigley ◽  
...  

2021 ◽  
pp. 1358863X2110386
Author(s):  
Pavel Kurianov ◽  
Alexandr Lipin ◽  
Alexey Antropov ◽  
Kirill Atmadzas ◽  
Nikita Gruzdev ◽  
...  

Background: This retrospective comparative cohort study evaluated the clinical outcome of angiosome-guided endovascular arterial reconstructions in chronic limb-threatening ischemia (CLTI) due to multilevel peripheral artery disease (PAD). Methods: Patients treated in an endovascular fashion for CLTI with tissue loss due to multilevel PAD were analyzed. Limbs were classified as having undergone either angiosome-guided (direct) revascularization (DR) or nonangiosomic (indirect) revascularization (IR). DR was defined as uninterrupted in-line flow to the affected angiosome, revascularization through the pedal arch was also considered direct. Groups were adjusted with propensity score (PS) matching and compared for amputation-free survival (AFS), freedom from major adverse limb events (MALE), and healing rate at 12 months. Results: A total of 174 patients (81 men, mean age 70.0 ± 10.4 y) were included. PS matching produced two groups of 55 patients each: DR (24 men, mean age 71.7 ± 10.7 y) and IR (26 men, mean age 72.0 ± 9.4 y). The matched groups had no significant differences in baseline variables. At 12 months there were no significant differences in AFS (73.2% vs 71.6%; p = 0.841), freedom from MALE (71.7% vs 66.1%; p = 0.617), and healing rate (72.7% vs 72.0%; p = 1.000) between DR and IR, respectively. Conclusion: This study failed to support the use of angiosome concept in CLTI due to multilevel disease.


Author(s):  
Katriina Heikkilä ◽  
Jaana Pentti ◽  
Ida E. H. Madsen ◽  
Tea Lallukka ◽  
Marianna Virtanen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document